Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style Sco ...

Core Viewpoint - Medtech Products Inc. is voluntarily recalling five lots of Little Remedies® Honey Cough Syrup due to contamination with Bacillus cereus and loss of shelf-stability, which poses health risks to consumers [1][2]. Group 1: Recall Details - The affected lots were distributed nationwide in the U.S. through retailers and online from December 14, 2022, to June 4, 2025 [2]. - The specific lot numbers and expiration dates of the recalled products are provided, including UPC codes [3]. Group 2: Product Information - Little Remedies® Honey Cough Syrup is packaged in a 4 FL OZ (118 mL) amber bottle, with lot codes visible on both the bottle label and the carton [4]. - This recall does not affect any other products under the Little Remedies® brand [4]. Group 3: Consumer Guidance - Consumers are advised to stop using the recalled product immediately and consult healthcare providers if they experience any related health issues [8]. - The company will provide reimbursement for consumers who purchased the affected lots [8]. Group 4: Reporting and Compliance - The recall is being conducted with the knowledge of the U.S. Food and Drug Administration [10]. - Consumers can report adverse reactions or quality issues through the FDA's MedWatch Adverse Event Reporting program [9].

Prestige Consumer Healthcare (PBH) FY Conference June 11, 2025 10:30 AM ET Speaker0 Good morning, everyone, and thank you for joining us at Oppenheimer's twenty fifth Annual Consumer Growth and Ecommerce Conference. My name is Rupesh Parikh. I'm the senior food, grocery, and consumer products analyst here at Oppenheimer. I'm happy to introduce our next presenting company, Prestige Consumer Healthcare. Joining us today are CEO, Ron Lombardi and VP, IR, and Treasury, Phil Turpolili. Prestige sells and distrib ...

Safe Harbor Disclosure This presentation contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company's expected financial performance, including revenues, organic revenue growth, diluted EPS, and free cash flow; the Company's reinvestment in Clear Eyes as supply increases; the Company's ability to execute on its brand- building strategy and to drive free cash flow and maximize shareholder value; e-commerce ...

Key Takeaways PBH gains from digital strategies, e-commerce momentum and niche brand innovations like Hydralyte. Acquisitions and product diversity help PBH minimize category-specific slowdowns and market volatility. Long-term debt of $1.01B and forex risks challenge PBH's profitability despite solid revenue growth forecasts.Prestige Consumer Healthcare’s (PBH) long-term growth strategy centers on building great brands. The company continues to experience robust momentum in the e-commerce channel as a res ...

Prestige Consumer (PBH) has witnessed strong momentum in the past year. Shares of the company have risen 35.7% compared with 7.9% growth of the industry during the same time frame. The S&P 500 composite has increased 9.3%.With healthy fundamentals and strong growth opportunities, this Zacks Rank #2 (Buy) company appears to be a solid wealth creator for its investors at the moment.Prestige Consumer develops, manufactures, markets, sells and distributes over-the-counter (OTC) healthcare and household cleaning ...

Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and EssilorLuxottica Unsponsored ADR (ESLOY) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ____________ Commission file number: 001-32433 PRESTIGE CONSUMER HEALTHCARE INC. (Exact name of registrant as specified in its charter) Delaware 20-12975 ...

Prestige Consumer Healthcare (PBH) Q4 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Phil Terpolilli - Vice President of Investor Relations & TreasurerRonald Lombardi - Chairman, President & CEOChristine Sacco - CFO & COOKeith D - Vice PresidentDouglas Lane - Head of Consumer Products Conference Call Participants Rupesh Parikh - Managing Director and Senior AnalystSusan Anderson - Managing Director & Senior AnalystNone - AnalystAnthony Lebiedzinski - Senior Equity Research Analyst Operator ...

Prestige Consumer Healthcare (PBH) Q4 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 and thank you for standing by. Welcome to the Prestige Consumer Healthcare's Fourth Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Phil Turpoli, Vice ...